New drug cocktail aims to shrink Hard-to-Treat tumors

NCT ID NCT07669415

Recruiting now Disease control Sponsor: LaNova Medicines Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LM-168 (a drug) combined with tislelizumab or docetaxel
What this could lead to: If successful, this could point toward a new combination treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early Phase 2 trial with only 108 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Peking University Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 201210, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.